



# LKT Laboratories, Inc.

## Raloxifene Hydrochloride

Phone: 888-558-5227  
651-644-8424  
Fax: 888-558-7329  
Email: [getinfo@lktlabs.com](mailto:getinfo@lktlabs.com)  
Web: [lktlabs.com](http://lktlabs.com)

### Product Information

**Product ID** R0243

**CAS No.** 82640-04-8

**Chemical Name** [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]- [4-[ 2-(1-piperidinyloxy) ethoxy] phenyl]methanone hydrochloride

**Synonym** Evista

**Formula** C<sub>28</sub>H<sub>27</sub>NO<sub>4</sub>S • HCl

**Formula Wt.** 510.05

**Melting Point** 258° C


**Purity** ≥98%

**Solubility** Very slightly soluble in water. Soluble in DMSO at 28 mg/mL.

**Store Temp** Ambient

**Ship Temp** Ambient

**Description** Raloxifene is a selective estrogen receptor modulator (SERM) that exhibits agonist activity in bone and antagonist activity in uterine and breast tissues. Raloxifene is clinically used to prevent osteoporosis in post-menopausal women and to treat ER+ breast cancer. This compound exhibits anti-osteoporotic, anti-parasitic, neuromodulatory, and anticancer chemotherapeutic activities. Raloxifene decreases fracture risk and enhances bone strength in clinical settings. In vitro and in vivo, raloxifene inhibits growth of *Leishmania* and parasitic burden. Additionally, raloxifene increases uptake of glutamate and expression of GLT-1 in astrocytes. In animal models of breast cancer, this compound decreases expression of EGFR, vascular density, and tumor growth.



**Bulk quantities available upon request**

Product ID	Size
R0243	50 mg
R0243	250 mg
R0243	500 mg
R0243	1 g

**References** Karki P, Webb A, Zerguine A, et al. Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes. *Glia*. 2014 Aug;62(8):1270-83. PMID: 24782323.

Reimão JQ, Miguel DC, Taniwaki NN, et al. Antileishmanial activity of the estrogen receptor modulator raloxifene. *PLoS Negl Trop Dis*. 2014 May 8;8(5):e2842. PMID: 24810565.

Gallant MA, Brown DM, Hammond M, et al. Bone cell-independent benefits of raloxifene on the skeleton: a novel mechanism for improving bone material properties. *Bone*. 2014 Apr;61:191-200. PMID: 24468719.

Taurin S, Allen KM, Scandlyn MJ, et al. Raloxifene reduces triple-negative breast cancer tumor growth and decreases EGFR expression. *Int J Oncol*. 2013 Sep;43(3):785-92. PMID: 23842642.

Gizzo S, Saccardi C, Patrelli TS, et al. Update on raloxifene: mechanism of action, clinical efficacy, adverse effects, and contraindications. *Obstet Gynecol Surv*. 2013 Jun;68(6):467-81. PMID: 23942473.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.